|Articles|May 3, 2021

ERT and Bioclinica Close Merger

ERT has announced the close of its merger with Bioclinica. The transaction combines Bioclinica’s imaging knowledge, eClinical software, and drug safety solutions with ERT’s knowledge in eCOA, cardiac safety, respiratory and wearables.

Joe Eazor is the CEO of the merged company, and the management team will be composed of a combination of both ERT and Bioclinica executives.

For more information, click here.

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

ERT and Bioclinica Close Merger

Related Content

Introducing The Human Side of Clinical Trials

ACT Brief: RBQM Financial Value Quantification, Trial Budget Cost Visibility Gap, and GSK mRNA Flu Vaccine Phase III

Why Quantifying the Financial Value of RBQM Has Been So Hard—and What This Study Did Differently

From Perspective to Action: Addressing the Real Cost Pressures in Clinical Trial Budgeting

ACT Brief: Operating Model Change Before AI, Workforce Compression Through Integration, and Cevumeran Trial Termination

Trending on Applied Clinical Trials Online

Workforce Compression in AI-Driven Clinical Trial Operations

From Perspective to Action: Addressing the Real Cost Pressures in Clinical Trial Budgeting

Navigating the Adoption of Biomarker-Informed Trial Enrollment Beyond Oncology

Agentic AI and the Administrative Backbone of Clinical Trials: Why the Operating Model Has to Change First

ACT Brief: Site Cash Runway and Payment Infrastructure Priority, Biomarker Cut-Off Selection and Disparities, and Batch Failure Prevention Systems